Briefing
Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapy.
A single-center prospective study used Guardant Reveal to test whether ctDNA after definitive therapy for oligometastatic colorectal cancer was associated with outcome.
- Design: Evidence level 3
- Assay: Guardant Reveal
Journal of Gastrointestinal OncologyPubMed 40386606DOI 10.21037/jgo-24-819